Research

ABK Biomedical is a unique Y90 microspheres and bland embolic microspheres company. Our proprietary Eye90 microspheres® and Easi-Vue™ microspheres are produced at our Halifax, Nova Scotia manufacturing facility.

Click the images below to check out our state of the art manufacturing facility in more detail.

Products

Products

CBCT, Porcine Renal Injection, Eye90 Microspheres®

Radiopaque Y90 Microspheres for The Treatment of Hepatic Tumors

ABK Biomedical’s most advanced microspheres product in development is Eye90 Microspheres®.  Eye90 microspheres® is a breakthrough technology for radioembolization made with a proprietary, radiopaque glass composition for procedure visualization via fluoroscopy, x-ray, CT and Cone Beam CT imaging modalities. 

Eye90 Microspheres®: An advanced new therapy designed to improve the placement precision of Y90 microspheres, with the potential to provide in-procedure prognostic dosimetry for cutting-edge treatment of liver tumors.

ABK Biomedical Inc. is a Pre-clinical stage company engaged in active research and development of new medical devices. ABK products are considered investigational only and are not FDA cleared for use.

Triscaryl gelatin microspheres (left) versus Easi-Vue™ embolization microspheres (right)

Radiopaque Microspheres for Bland Embolization

ABK Biomedical’s unique bland embolic product is Easi-Vue™, a tailored radiopaque permanent embolization microsphere. Easi-Vue embolization microspheres are being developed in a range of microsphere sizes that are inherently radiopaque for direct visualization of the embolic at the target site​ during embolotherapy.  

ABK Biomedical Inc. is a Pre-clinical stage company engaged in active research and development of new medical devices. ABK products are considered investigational only and are not FDA cleared for use.

Scientific Research

Scientific Research

GEST 2019

Bob Abraham, MD, CMO at ABK Medical recently presented the latest advances in radioembolization at the GEST 2019 Annual Meeting.

Click the link on the left to view and download Dr Abrahams presentation

Biomedical Physics & Engineering Express – August 2019

ABK Biomedical and collaborators from Dalhousie University and MD Anderson Cancer Center in Houston recently published a paper entitled Quantification of the inherent radiopacity of glass microspheres for precision dosimetry in yttrium-90 radioembolization.

Click the link on the left to view and download the abstract for this peer reviewed publication

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada
E. 
info@abkbiomedical.com
T. 902.442.4009

 

Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694
USA
E. 
info@abkbiomedical.com

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical may change the products mentioned at any time without notice. ABK Biomedical Inc. is a Pre-clinical stage company engaged in the active research and development of new medical devices. ABK Biomedical products are considered investigational only and are not FDA cleared for use..

(C) Copyright 2019 – All International Rights Reserved – ABK Biomedical Inc.